Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04993690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04993690 · ClinicalTrials.gov record · last posted 2025-09-23

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

StatusRecruiting
PhasePhase 1
Started2021-07-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2021-08-03; most recent amendment 2025-09-18. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT04993690
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions B-cell Lymphoma
Enrollment 200 participants
Start Date 2021-07-06
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-23